No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Aidea Pharmaceutical Gets Clinical Trial Approval for AD108 Injection
Jiangsu Aidea Pharmaceutical (688488.SH): AD108 injection has received the drug clinical trial approval notice.
On March 13, 2023, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its holding subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., received the "Notice of Drug Clinical Trial Approval" (referred to as the "Notice") issued by the National Medical Products Administration on March 12, 2025, approving the company to conduct Phase I clinical trials of the 2.2 class modified new drug AD108 injection. AD108 injection is a modified new drug (Chemical Drug class 2.2), with the active ingredient being human prorenin enzyme, specifically tissue type kallikrein-1 (KLK-1), which is a serine protease secreted by the kidneys.
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Looks Just Right With A 28% Price Jump
Eddy Pharmaceuticals 2024 Annual Results Express Announcement
Jiangsu Aidea Pharmaceutical (688488.SH): Net loss of 0.13 billion yuan for the year 2024.
Gelonghui February 27丨Jiangsu Aidea Pharmaceutical (688488.SH) announced the performance report for 2024. During the reporting period, the company's total operating revenue was 419.265 million yuan, an increase of 1.92% compared to the same period last year; the operating profit was -151.8265 million yuan, which is a decrease of 64.94% compared to the same period last year; the total profit was -153.0564 million yuan, which represents a decrease of 66.21% compared to the same period last year; the net income attributable to the owners of the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the same period last year; the net income attributable to the owners of the parent company after deductions.
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You